Brentuximab Vedotin: 12 agencies, 2013–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 12.6 years separate the first record, 20 Mar 2013 at HAS (France), from the most recent, 24 Oct 2025 at AOTMIT (Poland).
DMC (Denmark) changed its position: not recommended on 15 Aug 2018, restricted by 24 Feb 2021, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for brentuximab vedotin.
Not every gap is a refusal: for brentuximab vedotin, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 11 of 54 records date from 2023 or later.
The programme is broad: 16 distinct indication wordings are recorded for brentuximab vedotin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 54 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess brentuximab vedotin, on 20 Mar 2013; CIPM (Spain) did not open a file until 28 Oct 2021 — an unusually long tail of 8.6 years between the earliest and latest system to look at it.
The record arrives in waves: 11 separate years each carry two or more decisions, spread across 13 years in total.
Restriction is doing real work here: 15 of 44 decisive outcomes narrowed brentuximab vedotin to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), AOTMIT (Poland) and DMC (Denmark) among others.
12 of the 12 agencies here assessed brentuximab vedotin more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
brentuximab vedotin has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for brentuximab vedotin reads 18 recommended, 15 restricted, 11 not recommended and 4 deferred to NICE, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 11 Aug 2025 | Treatment of adult patients with previously untreated cell membrane receptor 30-positive (CD30+) Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vi… | accepted | source |
| CIPM (Spain) | 16 Jul 2025 | Indicaciones terapéuticas autorizadas: Linfoma de Hodgkin ADCETRIS está indicado para pacientes adultos con linfoma de H… | not financed by the SNS · art. 92 d, e | source |
| PBAC (Australia) | 2025 | Hodgkin lymphoma | Recommended | source |
| NICE (England) | 7 May 2025 | NICE TA1059 | terminated appraisal | source |
| AOTMIT (Poland) | 25 Aug 2023 | Adcetris reimbursement recommendation | recommended conditionally | source |
49 further decisions for brentuximab vedotin, across 12 agencies, are not shown here. They include the most recent record on file, 24 Oct 2025 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 36 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 54 decisions for brentuximab vedotin from 12 agencies, 2013 to 2025. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.